Related references
Note: Only part of the references are listed.Prognostic effect of estrogen receptor status across age in primary breast cancer
Niels Bentzon et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen
H. F. Kennecke et al.
ANNALS OF ONCOLOGY (2007)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Meeting highlights:: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
A Goldhirsch et al.
ANNALS OF ONCOLOGY (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004
EP Winer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies
SK Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Treatment of lymph-node-negative, oestrogen-recept-postive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials
B Fisher et al.
LANCET (2004)
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
PE Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma - Final analysis with 10-year follow-up
V Assikis et al.
CANCER (2003)
Estrogen receptors and distinct patterns of breast cancer relapse
KR Hess et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
B Fisher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years
HJ Stewart et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Share Paper
